Review articleBackground and rationale for the Sequenced Treatment Alternatives to Relieve Depression (STAR∗D) study☆
Section snippets
MDD is a common condition
Major depressive disorder is a common, often chronic or episodic lifelong disorder that is associated with substantial disability and mortality. Although a range of effective treatments is available, a substantial proportion of patients do not respond adequately to treatment in those instances. Which treatments to use alone or in combination, and in what sequence they should be implemented, is not well-defined. As a result, current treatment guidelines rest substantially on open consecutive
Definition
Although the aim of treatment for depression is complete symptom remission and complete functional restoration [12], [30], [31], no single treatment is a panacea. The clearly preferred outcome is sustained clinical remission (ie, the absence of depressive symptoms) and full functional restoration. Based on randomized, placebo-controlled medication trials conducted for regulatory approval, about 50% to 60% of depressions respond to the first treatment, and about 35% to 40% achieve remission in
Evidence to define the next steps
Many treatments for depression have established efficacy in randomized controlled trials [1]. The actual acceptability, clinical benefit, and side effect burden of these treatments in populations representative of every day practice, however, is less well known. In addition, it remains unclear how to treat MDD that responds but does not remit with an initial antidepressant treatment. Response without full remission to antidepressant treatment is frequent [2], and is associated with continuing
Need for representative patients
Most efficacy studies have excluded participants with common general medical and psychiatric comorbidities. Generalization of even these tentative findings to representative populations is difficult. The proposed study has very broad inclusion criteria that allow enrollment of both adult and elderly patients, and clinically depressed patients with many other psychiatric comorbidities. General medical comorbidities are also allowed, as long as clinicians consider antidepressant treatment
Routine versus high-quality treatment
The implementation of treatments under evaluation in STAR∗D must be well enough conducted to ensure actual, not apparent, treatment resistance, yet must be representative of good practice. Treatments must also be tailored to individual participants with general medical, ethnic, and psychiatric diversity. This tension between generalizability and protocol adherence results in a need for a spectrum of clinically acceptable variations (ie, variations that do not profoundly affect outcomes or that
Domains of outcome
STAR∗D includes assessments of several domains: symptoms, function, quality of life, side effect burden, participant satisfaction, and health care utilization and cost.
Primary objectives
The STAR∗D uses a prospective design to determine the comparative effectiveness of different treatment options for MDD. It evaluates the comparative effectiveness of treatments when used either as augmenting treatments or as new treatments when remission is not attained with an initial SSRI CIT. STAR∗D provides several levels or steps in treatment following CIT failure. Assignment to multiple treatments at each level is randomized at all treatment levels (2, 2A, 3, and 4). Clinical outcomes
Equipoise versus forced randomization
From the 4000 participants who enter the STAR∗D treatment protocol, 2000 participants are expected not to have a satisfactory therapeutic response to CIT. These 2000 individuals are eligible for seven different treatment options at level 2. These options may be conceptualized as representing two overall treatment strategies: medication or psychotherapy switch, switching from CIT to another antidepressant medication or CT; and medication or psychotherapy augmentation, augmenting CIT with a
Tactical issues
The STAR∗D ensures that only participants who are treatment-resistant or intolerant enter each subsequent treatment level. It is essential that participants with merely “apparent treatment resistance” to inadequate treatment do not move to the next treatment level (ie, those without an adequate drug dose or an adequate duration of treatment at the prior level) [139]. The issues of dose and duration (for both medication and psychotherapy) are termed treatment tactics [32], [35], [140]. Current
Prediction of response or remission
The degree to which the type of initial treatment, type of depression (melancholic versus atypical), demographic parameters (eg, age, gender, or socioeconomic status), and coexisting axis I and III disorders affects the duration of an adequate trial, and the likelihood and timing of response must be ascertained.
Because STAR∗D strongly encourages 12 weeks of treatment with vigorous dosing at each level, it provides an opportunity to determine whether specific baseline features (patient, illness,
Prediction of relapse or recurrence
Very little is known about the long-term outcome of participants who successfully remit with an antidepressant, particularly if their remission follows nonresponse or partial response to a prior antidepressant trial. How long are they able to remain well? STAR∗D includes longitudinal, naturalistic 12-month follow-up of all participants who have a satisfactory response to any treatment option at any level. This population allows the investigation of possible clinical predictors of relapse or
Limitations of the protocol
The STAR∗D, although extensive, does not answer every question regarding the treatment of MDD. Only one form of psychotherapy is being evaluated (although other forms will be considered once the planned protocol is completed, if the National Institutes of Mental Health continues support). To ensure sufficient homogeneity and sample size, the authors had to begin with a single treatment at level 1, rather than several. The multiple roles or preferred positions in the randomization scheme for
Issues in dissemination of findings
Despite the high prevalence of MDD and the availability of effective treatments, underdiagnosis and undertreatment remain the norm. Only one third to one half of individuals with MDD is properly recognized by practitioners, and even of those who are, many do not receive adequate treatment [144]. In a study by Wells et al [13] from data across treatment settings, only 11% of mildly depressed patients received an antidepressant and 29% of patients of high severity received an antidepressant. Of
References (159)
- et al.
Definition and epidemiology of treatment-resistant depression
Psychiatr Clin North Am
(1996) Predictors of persistent social impairment among recovered depressed outpatients
J Affect Disord
(1999)- et al.
Recovery, chronicity, and levels of psychopathology in major depression
Psychiatr Clin North Am
(1996) - et al.
A prospective test of criteria for response, remission, relapse, recovery, and recurrence in patients treated with cognitive behavior therapy
J Affect Disord
(1997) Subaffective disorders: dysthymic, cyclothymic, and bipolar II disorders in the “borderline” realm
Psychiatr Clin North Am
(1981)- et al.
After lithium augmentation: a retrospective follow-up of patients with antidepressant-refractory depression
J Affect Disord
(1990) - et al.
High-dose fluoxetine in the treatment of depressed patients not responsive to a standard dose of fluoxetine
J Affect Disord
(1992) - et al.
A double-blind, placebo-controlled study of mirtazapine augmentation for refractory depression
Biol Psychiatry
(2002) - et al.
Efficacy of treatments for major depression
Psychopharmacol Bull
(1993) - et al.
Affective disorders
Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey
Arch Gen Psychiatry
Diagnostic and statistical manual of mental disorders
Results of the DSM-IV Mood Disorders Field Trial
Am J Psychiatry
A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders
Arch Gen Psychiatry
Refractory depression: relevance of psychosocial factors and therapies
Psychiatr Ann
The functioning and well-being of depressed patients: results from the Medical Outcomes Study
JAMA
Evidence-based health policy: lessons from the Global Burden of Disease Study
Science
The economic burden of depression in 1990
J Clin Psychiatry
Health care costs of primary care patients with recognized depression
Arch Gen Psychiatry
The clinical course of unipolar major depressive disorders
Arch Gen Psychiatry
Socioeconomic burden of subsyndromal depressive symptoms and major depression in a sample of the general population
Am J Psychiatry
The treatment of chronic depression,Part 3: Psychosocial functioning before and after treatment with sertraline or imipramine
J Clin Psychiatry
Treating depression to remission
Psychiatr Ann
Pharmacy-enforced outpatient drug treatment protocols: a case study of Medical restrictions for cefaclor
Ann Pharmacother
Short-term psychotherapy of depressive disorders: current status and future directions
Psychiatry: Interpers Biol Process
Conceptualization and rationale for consensus definitions of response, remission, recovery, relapse and recurrence in major depressive disorder
Arch Gen Psychiatry
A rating scale for depression
J Neurol Neurosurg Psychiatry
Development of a rating scale for primary depressive illness
Br J Soc Clin Psychol
Psychotherapies for depressive disorders
General health, health care utilization, and medical comorbidity in dysthymia
Int J Psychiatr Med
Practice guideline for major depressive disorder in adults
Am J Psychiatry
Practice guideline for the treatment of patients with major depressive disorder
Am J Psychiatry
The Texas Medication Algorithm Project. Report of the Texas Consensus Conference Panel on medication treatment of major depressive disorder
J Clin Psychiatry
Texas Medication Algorithm Project: definitions, rationale and methods to develop medication algorithms
J Clin Psychiatry
The Inventory of Depressive Symptomatology (IDS): Clinician (IDS-C) and Self-Report (IDS-SR) ratings of depressive symptoms
Int J Methods Psychiatric Res
From scientific knowledge to the clinical practice of psychopharmacology: Can the gap be bridged?
Psychopharmacol Bull
Continuation and maintenance treatments of major depressive disorder
Psychiatr Ann
The treatment of chronic depression,Part 2: A double-blind, randomized trial of sertraline and imipramine
J Clin Psychiatry
Pharmacological strategies for treatment-resistant major depression
Treatment-resistant mood disorders
Psychiatrists' responses to failure of maintenance therapy with antidepressants
Psychiatr Serv
Three-year outcomes for maintenance therapies in recurrent depression
Arch Gen Psychiatry
Relationship of pharmacologic compliance to long-term prophylaxis in recurrent depression
Psychopharmacol Bull
Venlafaxine and paroxetine in treatment-resistant depression: double-blind, randomized comparison
Br J Psychiatry
Treatment-resistant depression
When at first you don't succeed: sequential strategies for antidepressant nonresponders
J Clin Psychiatry
…and a small dose of an antidepressant might help
Br J Psychiatry
Antidepressants may not assist recovery in practice: a naturalistic prospective study
Acta Psychiatr Scand
Cited by (0)
- ☆
Supported in part by National Institutes of Mental Health Contract N01-MH-90003, the Betty Jo Hay Distinguished Chair in Mental Health, the Rosewood Corporation Chair in Biomedical Science, and the Sara M. and Charles E. Seay Center for Basic and Applied Research in Psychiatry.